Tempus AI, Inc. $TEM Stock: International Assets Investment Management LLC Grows Stake

Key Points

• International Assets Investment Management increased its Tempus AI stake by 3,027.6% in the third quarter, acquiring 101,212 additional shares and bringing its holdings to 104,555 shares valued at approximately $8.56 million. Institutional investors collectively own 24.22% of the company.
• Analyst opinions remain mixed: 11 analysts rate the stock Buy, nine Hold, and two Sell. The consensus rating is Hold, with an average price target of $72.47.
• Tempus AI reported quarterly revenue of $382.49 million, up 21.6% year over year, and an adjusted loss of $0.04 per share that beat estimates. The stock opened at $72.22, with a 12-month range of $40.77 to $90.53, while insiders sold about $87.5 million worth of shares over the past three months.

International Assets Investment Management LLC grew its stake in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) by 3,027.6% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 104,555 shares of the company's stock after acquiring an additional 101,212 shares during the quarter. International Assets Investment Management LLC owned about 0.06% of Tempus AI worth $8,563,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. V Square Quantitative Management LLC bought a new position in shares of Tempus AI in the third quarter worth $27,000. EMC Capital Management bought a new stake in Tempus AI during the second quarter worth about $29,000. Ulland Investment Advisors LLC bought a new stake in Tempus AI during the third quarter worth about $41,000. Eastern Bank acquired a new stake in Tempus AI during the third quarter worth about $69,000. Finally, Whittier Trust Co. grew its stake in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company's stock worth $41,000 after buying an additional 570 shares in the last quarter. Institutional investors own 24.22% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. The Goldman Sachs Group initiated coverage on shares of Tempus AI in a research report on Monday, September 21st. They issued a "neutral" rating and a $75.00 target price for the company. Lake Street Capital lowered shares of Tempus AI to a "hold" rating in a research report on Monday, July 20th. Piper Sandler raised shares of Tempus AI from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Cantor Fitzgerald initiated coverage on shares of Tempus AI in a research note on Wednesday, September 2nd. They issued an "overweight" rating and a $80.00 price objective on the stock. Finally, Rothschild & Co Redburn assumed coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They set a "neutral" rating and a $67.00 price objective for the company. Eleven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $72.47.

Tempus AI Stock Performance

NASDAQ:TEM opened at $72.22 on Friday. The stock's 50-day simple moving average is $70.69 and its 200 day simple moving average is $57.07. The firm has a market capitalization of $13.03 billion, a PE ratio of -50.15 and a beta of 3.54. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $90.53.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to analysts' expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The business's revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.22) earnings per share. On average, analysts anticipate that Tempus AI, Inc. will post -1.45 EPS for the current fiscal year.

Insider Activity at Tempus AI

In other news, EVP Andrew Polovin sold 22,148 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $1,098,762.28. Following the sale, the executive vice president directly owned 146,067 shares in the company, valued at approximately $7,246,383.87. This trade represents a 13.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of the firm's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the sale, the chief executive officer owned 562,463 shares in the company, valued at approximately $27,903,789.43. The trade was a 6.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,280,965 shares of company stock worth $87,472,564 over the last three months. 24.26% of the stock is owned by insiders.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.